摘要 |
<p>The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.</p> |
申请人 |
MERCK SHARP & DOHME CORP.;PHARMACOPEIA, LLC |
发明人 |
KIM, SEONG, HEON;ANILKUMAR, GOPINADHAN, N.;WONG, MICHAEL, K. C.;ZENG, QINGBEI;ROSENBLUM, STUART, B.;KOZLOWSKI, JOSEPH, A.;SHAO, YUEFEI;MC GUINNESS, BRIAN, F.;HOBBS, DOUGLAS, W. |